suppressive than CY alone. Prompted by this success, Storb et al 7 have used CY/ATG to condition patients with aplastic anemia for first transplant, resulting in 92% 3-year actuarial Graft rejection has been a problem after bone marrow transplantation for patients with severe aplastic anemia survival. Based on favorable experience in Seattle, Horstmann et al, 8 Okamoto et al 9 and Bunin et al 10 reported (SAA). Ten children with SAA were conditioned for bone marrow transplantation from HLA-identical sibsimilar results, using a different source, dose, and time schedule of ATG. Here, we report our results of CY/ATG lings, using cyclophosphamide (CY, 50 mg/kg) plus antithymocyte globulin (ATG, 15 mg/kg ) for 4 successive conditioning in 10 children with SAA; a durable engraftment rate of 100% in a median follow-up of 25 days. Marrow was infused 36 h after the last dose of CY. Cyclosporin A and methotrexate were administered months. Furthermore, in an effort to better understand the post-transplant experience of these patients, we compared as graft-versus-host disease (GVHD) prophylaxis. All patients achieved durable engraftment at follow-up of current results with published reports. 7-41+ months (mean, 25) without significant GVHD. Since investigators have used different sources, doses, and time schedules of ATG, we compared our results Patients and methods with other published reports. We conclude that CY/ATG conditioning is well tolerated and effective in From
of skin rashes and/or fevers in eight of 10 patients. Followyears. All had developed SAA of idiopathic etiology. Three up for these patients is from 7-41+ months (median, 25.2) patients (Nos 3, 4 and 6) had received prior therapy with with durable engraftment rate of 100%. The Karnofsky steroids, G-CSF, M-CSF, CsA, or androgen, and all had score is 100%. Second cancers or other serious long-term received transfusions; red blood cells (RBC) and platelets sequelae of the conditioning regimen have not been were administered 4-14 units (mean, 7.8) and 3-70 units observed during the current follow-up. Transfusions increase the risk of sensitization, and subsequent graft rejection in patients with SAA following Engraftment and GVHD BMT. 2 Given the difficulty in avoiding transfusions before transplant, more effective approaches have been explored Table 1 summarizes the transplantation data and results. All 10 patients showed evidence of hematopoietic engraftment to reduce the risk of graft rejection. Despite the unequivocal success with the irradiation-based regimens, concern has as determined by rising peripheral blood counts, marrow cellularity, and blood genetic marker studies. The median been raised by a publication reporting a high incidence of secondary malignancies. 5 However, the treatment of SAA time to reach absolute neutrophil counts of 500 was 17.2 days post-transplant (range, 11-33). One patient (No. 7) with immunosuppressive therapy alone also has an increased incidence of second malignancy. 5 Kalamazoo, MI, USA) as a conditioning regimen for BMT
